Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Thyroid Carcinoma, Anaplastic 2Respiratory Tract Neoplasms 2Colorectal Neoplasms 2Thyroid Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Advanced Non-small Cell Lung Cancer (NSCLC) 1Advanced Cancer 1

Interventions

Paclitaxel 3Carboplatin 3selpercatinib 2pralsetinib 2efatutazone 2Pemetrexed 2Erlotinib Hydrochloride 2sotorasib 1pembrolizumab 1patritumab 1osimertinib 1napabucasin 1durvalumab 1cobimetinib 1atezolizumab 1alectinib 1Tyrosine Kinase Inhibitors 1Radiosurgery 1Gemcitabine 1Dasatinib 1Cisplatin 1Bevacizumab 1Afatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Respiratory Tract Neoplasms × efatutazone × Clear all
NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
15 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT01199055 2020-07-07

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Daiichi Sankyo

Phase 1 Completed
16 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡